GlassScriptPhysician profile
Yelena Shpigel
NPI 1205888377
$18,019.45
in general payments reported to CMS, 2019-2025
62 companies · $34.38 in 2025
The $34.38 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,324 · 2020: $2,347 · 2021: $3,067 · 2022: $4,009 · 2023: $3,487 · 2024: $1,751 · 2025: $34.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,272 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,271.54 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,074.44 | 2019-2024 | Mavenclad |
| Abbvie INC. | $1,495.70 | 2019-2024 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $1,429.37 | 2019-2024 | Briviact, Zilbrysq, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,041.28 | 2019-2024 | Austedo, Austedo Xr, Ajovy |
| Biogen, INC. | $1,006.60 | 2019-2023 | Tysabri, Plegridy, Avonex |
| Novartis Pharmaceuticals Corporation | $833.16 | 2019-2024 | |
| Amgen INC. | $820.18 | 2019-2024 | Aimovig |
| Sk Life Science, INC. | $752.29 | 2020-2024 | Xcopri |
| Jazz Pharmaceuticals INC. | $646.19 | 2019-2024 | |
| Lilly USA, LLC | $624.84 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Genzyme Corporation | $609.19 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $525.06 | 2019-2024 | Ultomiris, Soliris |
| Amneal Pharmaceuticals LLC | $432.96 | 2019-2023 | Rytary |
| Biohaven Pharmaceutical Holding Company LTD. | $329.57 | 2022 | |
| Acorda Therapeutics, INC | $299.84 | 2019-2023 | Inbrija |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Shpigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.